Adding palbociclib upped responses in previously treated MCLFebruary 15, 2019Lymphoma & Plasma Cell Disorders
EC approves BV plus AVD for Hodgkin lymphomaFebruary 15, 2019Hodgkin LymphomaLymphoma & Plasma Cell Disorders
Few DLBCL patients benefit from nivolumabFebruary 14, 2019Aggressive LymphomasLymphoma & Plasma Cell Disorders
Targeted triplet shows potential for B-cell cancersFebruary 14, 2019Lymphoma & Plasma Cell DisordersLeukemia, Myelodysplasia, Transplantation
Inhibitor risk nears zero after 75 days in previously untreated hemophilia AFebruary 13, 2019Bleeding DisordersPediatrics
FDA approves daratumumab split-dosing regimen in MMFebruary 13, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
EC approves dasatinib plus chemo for kids with Ph+ ALLFebruary 11, 2019ALLPediatricsLeukemia, Myelodysplasia, Transplantation
Anthracyclines, bendamustine are options for grade 3A follicular lymphomaFebruary 11, 2019Aggressive LymphomasLymphoma & Plasma Cell Disorders
Ibrutinib-MTX-rituximab combo shows promise in CNS lymphomaFebruary 11, 2019Aggressive LymphomasLymphoma & Plasma Cell Disorders
